Zura Bio Limited (NASDAQ:ZURA) Receives Average Rating of "Moderate Buy" from Analysts

Key Points

• Zura Bio has a “Moderate Buy” consensus rating from seven analysts: five buys, one strong buy, and one sell. The average 12-month price target is $17, well above the stock’s reported price of $5.38.
• Institutional investors own 61.14% of Zura Bio, with several hedge funds recently initiating or expanding positions, including Siren L.L.C., Montanova Capital, and Commodore Capital.
• Zura Bio reported a quarterly loss of $0.21 per share, while analysts expect a full-year loss of $0.81 per share. The clinical-stage biotechnology company is developing protein bioconjugates for oncology, immunology, and rare-disease applications.

Shares of Zura Bio Limited (NASDAQ:ZURA - Get Free Report) have been given a consensus rating of "Moderate Buy" by the seven analysts that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, five have issued a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $17.00.

Several analysts have commented on ZURA shares. William Blair assumed coverage on Zura Bio in a research note on Wednesday, July 8th. They set an "outperform" rating for the company. Wedbush boosted their target price on Zura Bio from $15.00 to $22.00 and gave the company an "outperform" rating in a report on Wednesday, August 12th. Weiss Ratings restated a "sell (d-)" rating on shares of Zura Bio in a research note on Monday, July 6th. Wall Street Zen raised Zura Bio from a "strong sell" rating to a "sell" rating in a report on Saturday, August 1st. Finally, Guggenheim increased their price target on Zura Bio from $15.00 to $20.00 and gave the stock a "buy" rating in a report on Wednesday, August 12th.

Hedge Funds Weigh In On Zura Bio

A number of large investors have recently bought and sold shares of the company. EcoR1 Capital LLC purchased a new stake in Zura Bio in the 1st quarter valued at approximately $7,019,000. Siren L.L.C. raised its stake in shares of Zura Bio by 187.3% during the 1st quarter. Siren L.L.C. now owns 3,734,866 shares of the company's stock worth $22,222,000 after buying an additional 2,434,866 shares in the last quarter. Stempoint Capital LP purchased a new position in shares of Zura Bio during the 1st quarter worth approximately $4,483,000. Montanova Capital LLC lifted its holdings in shares of Zura Bio by 4.1% in the 2nd quarter. Montanova Capital LLC now owns 9,443,001 shares of the company's stock valued at $55,714,000 after buying an additional 376,000 shares during the period. Finally, Commodore Capital LP purchased a new stake in shares of Zura Bio in the first quarter valued at approximately $19,338,000. Hedge funds and other institutional investors own 61.14% of the company's stock.

Zura Bio Stock Performance

Shares of NASDAQ:ZURA opened at $5.38 on Friday. The company has a 50-day simple moving average of $5.61 and a 200-day simple moving average of $5.36. Zura Bio has a one year low of $1.88 and a one year high of $7.44. The stock has a market capitalization of $515.57 million, a price-to-earnings ratio of -4.76 and a beta of -0.02.

Zura Bio (NASDAQ:ZURA - Get Free Report) last released its quarterly earnings results on Tuesday, June 30th. The company reported ($0.21) earnings per share (EPS) for the quarter. As a group, research analysts forecast that Zura Bio will post -0.81 EPS for the current fiscal year.

Zura Bio Company Profile

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.